Over ons
Handl Therapeutics, based in Leuven, is a newly created gene therapy company that operates a breakthrough adeno-associated virus (AAV) technology platform. Handl was recently acquired by UCB and will bring its platform technologies, pre-clinical programs & AAV expertise to the UCB family. Both companies have shared values and a deep interest in neurogenerative diseases.
Handl Therapeutics currently is in preclinical development with two programs in CNS, targeting Parkinson’s Disease and ALS, with the aim to enter the clinic in early 2022. The core focus is to develop AAV vectors that can be optimised for multiple neurodegenerative diseases.
The company has entered into exclusive collaborations with the KUL (Katholieke Universiteit Leuven), The Universidad de Navarra in Pamplona and the University of Santiago de Chile.
Handl Therapeutics is setting up labs in the KUL facilities in the Bioincubator in Leuven, and has additional programs collaborations with private and public institutions.
Handl Therapeutics plan to progress their first asset, targeting Parkinson’s Disease (PD), into the clinic by early 2022. This will be followed by a second asset 9 months later; to be followed by a pipeline of 3 further assets
